| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于提高蛋白质消化速率和吸收的蛋白酶及其使用方法 | CN201280069900.0 | 2012-12-11 | CN104470372A | 2015-03-25 | 马克·L·安德森 |
| 本发明涉及一种食品增补剂，其包含选自下列的至少一种蛋白酶：(i)CAS#9001-92-7，来自于曲霉属(Aspergillus)的IUB 3.4.23.18蛋白酶；(ii)CAS#9001-92-7，来自于芽孢杆菌属(Bacillus)的IUB3.4.21.7蛋白酶；(iii)CAS#9001-61-0，来自于曲霉属的IUB 3.4.11.1蛋白酶；(iv)CAS#9074-07-1，来自于曲霉属的IUB 3.4.21.63蛋白酶；(v)CAS#9073-78-3，来自于曲霉属的IUB 3.4.24.27蛋白酶；(vi)CAS#9025-49-4，来自于曲霉属的IUB 3.4.23.18蛋白酶；和(vii)它们的组合。所述食品增补剂还可以包含蛋白质、稳定剂、基质改良剂、载体、防腐剂、增量剂、干燥剂、乳化剂、酶涂层或其组合。本发明公开了一种增加蛋白质在人类胃肠系统中的吸收的方法，所述方法包括摄食如上指定的食品增补剂的步骤。 | ||||||
| 2 | 蜂蜜曲霉蛋白酶在用于去除细菌生物膜的用途 | CN201380036705.2 | 2013-05-10 | CN104602700A | 2015-05-06 | 磊·石; A·乔瓦诺维奇; C·范德卡尔; E·罗什 |
| 本发明公开了用于破坏存在于表面上的细菌生物膜的组合物和方法，所述方法包括将包含蜂蜜曲霉蛋白酶的组合物施用到所述细菌生物膜，其中将所述组合物施用到所述细菌生物膜破坏所述细菌生物膜的基质。 | ||||||
| 3 | 含有蜂蜜曲霉蛋白酶的伤口清创组合物和使用其治疗伤口的方法 | CN201280034373.X | 2012-05-11 | CN103687610A | 2014-03-26 | 磊·石; A·乔瓦诺维奇; D·卡森 |
| 含有蛋白水解酶蜂蜜曲霉蛋白酶(Seaprose)的伤口清创组合物及所述组合物在用于伤口的酶促清创的伤口治疗中的用途。 | ||||||
| 4 | 蛋白酶针对谷蛋白不耐受的用途 | CN201180008536.2 | 2011-02-02 | CN102858795A | 2013-01-02 | 詹姆斯·F·乔利; 井户宏树; 松原宽敬; 高桥哲也; 西尾享一 |
| 本发明的技术涉及酶组合物。所述酶组合物可以用来治疗谷蛋白不耐受性受试者，包括患有非乳糜泻谷蛋白不耐受和/或非乳糜泻谷蛋白敏感的受试者。所述酶组合物也可以用来减少某些个体中的谷蛋白暴露。例如，该酶组合物也可以用作预防药以减少对谷蛋白寡肽的暴露。 | ||||||
| 5 | 适于咀嚼或吞咽困难者的食品 | CN200880109875.8 | 2008-09-30 | CN101815442A | 2010-08-25 | 后藤礼佳; 竹井亮; 北村研; 杉村谦一郎; 栗林稔 |
| [课题]提供适于老年人或咀嚼/吞咽困难者的食品。[解决问题的方式]目标食材，其保持原材料的自然形态和色调，具有使得在口腔中用牙龈或舌头弄碎的软化度和平滑感，当通过使用直径为3mm的活塞，在压缩速度为10mm/sec下，同时将间隙(clearance)设定在样品厚度的30％测量时，显示压缩应力为5×104N/m2以下，所述食材通过用酶浸渍来酶处理原材料来获得。 | ||||||
| 6 | THERAPEUTIC COMPOUNDS AND FORMULATIONS FOR INTRANASAL DELIVERY | US15559408 | 2016-03-17 | US20180085306A1 | 2018-03-29 | Ronald A. Siegel; Mamta Kapoor; Narsihmulu Cheryala; Gunda I. Georg; James C. Cloyd |
| Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof. | ||||||
| 7 | WOUND DEBRIDEMENT COMPOSITIONS CONTAINING SEAPROSE AND METHODS OF WOUND TREATMENT USING SAME | US15417680 | 2017-01-27 | US20170136103A1 | 2017-05-18 | Lei SHI; Aleksa JOVANOVIC; Dennis CARSON |
| Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds. | ||||||
| 8 | Drug delivery method | US14909411 | 2014-07-31 | US10117912B2 | 2018-11-06 | Ronald A. Siegel; James Cloyd; Tate Winter; Mamta Kapoor |
| The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine. | ||||||
| 9 | EGG CHALAZA HYDROLYSATE, METHOD FOR PREPARING THE SAME AND USAGE OF THE SAME | US15658792 | 2017-07-25 | US20180117094A1 | 2018-05-03 | YI-CHEN CHEN; YU-XUAN LIN |
| An egg chalaza hydrolysate, a method for preparing the same and a usage of the same are revealed. An egg chalaza is hydrolyzed by an enzyme to get a hydrolysate solution. The hydrolysate solution is filtered and lyophilized to get an egg chalaza hydrolysate. The egg chalaza hydrolysate includes leucine, arginine, phenylalanine, valine, and lysine. The egg chalaza hydrolysate can reduce fat accumulation and oxidative stress in livers. Thus the egg chalaza hydrolysate is applied to prepare a composition for liver protection. | ||||||
| 10 | Enzyme inhibitors of PAI-1 | US11545015 | 2006-10-10 | US08066991B2 | 2011-11-29 | James F. Jolly |
| The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease in a subject who presents at least one risk factor that is associated with a cardiovascular disease, by administering to the subject a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. Additionally, the invention provides a method of inhibiting PAI-1 activity in a subject in need thereof, where the subject is administered an enzyme selected from a protease or peptidase. | ||||||
| 11 | Enzyme inhibitors of PAI-1 | US11545015 | 2006-10-10 | US20070081988A1 | 2007-04-12 | James Jolly |
| The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease in a subject who presents at least one risk factor that is associated with a cardiovascular disease, by administering to the subject a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. Additionally, the invention provides a method of inhibiting PAI-1 activity in a subject in need thereof, where the subject is administered an enzyme selected from a protease or peptidase. | ||||||
| 12 | 増大した蛋白質の消化速度及び吸収のためのプロテアーゼ酵素とそれを用いる方法 | JP2014549116 | 2012-12-11 | JP2015501661A | 2015-01-19 | マーク エル アンダーソン |
| 補助食品が、(i)CAS#9001−92−7、IUB3.4.23.18のプロテアーゼ(アスペルギルス由来)、(ii)CAS#9001−92−7、IUB3.4.21.7のプロテアーゼ(バシラス由来)、(iii)CAS#9001−61−0、IUB3.4.11.1のプロテアーゼ(アスペルギルス由来)、(iv)CAS#9074−07−1、IUB3.4.21.63のプロテアーゼ(アスペルギルス由来)、(v)CAS#9073−78−3、IUB3.4.24.27のプロテアーゼ(アスペルギルス由来)、(vi)CAS#9025−49−4、IUB3.4.23.18のプロテアーゼ(アスペルギルス由来)、及び(vii)それらの組み合わせから選択される、少なくとも1つのプロテアーゼ酵素を含む。前記補助食品は、蛋白質、安定化剤、基質改良剤、担体、保存料、賦形剤、乾燥剤、乳化剤、酵素コーティング、又はそれらの組み合わせをさらに含み得る。上記の補助食品を摂取するステップを含む、蛋白質吸収をヒトの消化器系において増大させる方法が開示される。 | ||||||
| 13 | Enzyme inhibitor of Pai-1 | JP2008535603 | 2006-10-10 | JP5242402B2 | 2013-07-24 | ジョリー，ジェームズ，エフ． |
| 14 | SEAPROSE FOR REMOVING BACTERIAL BIOFILM | EP13724135.2 | 2013-05-10 | EP2849777B1 | 2017-10-18 | SHI, Lei; JOVANOVIC, Aleksa; VAN DER KAR, Catherine; ROCHE, Eric |
| 15 | DRUG DELIVERY METHOD | EP14750955.8 | 2014-07-31 | EP3027202A1 | 2016-06-08 | SIEGEL, Ronald A.; CLOYD, James; WINTER, Tate; KAPOOR, Mamta |
| The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine. | ||||||
| 16 | USE OF SEAPROSE TO REMOVE BACTERIAL BIOFILM | EP13724135.2 | 2013-05-10 | EP2849777A1 | 2015-03-25 | SHI, Lei; JOVANOVIC, Aleksa; VAN DER KAR, Catherine; ROCHE, Eric |
| Disclosed are compositions and methods for their use in disrupting a bacterial biofilm present on a surface, comprising applying a composition that includes Seaprose to the bacterial biofilm, wherein application of the composition to the bacterial biofilm disrupts the matrix of the bacterial biofilm. | ||||||
| 17 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | EP11740281.8 | 2011-02-02 | EP2531521B1 | 2017-09-06 | JOLLY, James, F.; IDO, Horoki; MATSUBARA, Hirotaka; TAKAHASHI, Tetsuya; NISHIO, Kyoichi |
| 18 | USE OF PROTEASES FOR GLUTEN INTOLERANCE | EP11740281 | 2011-02-02 | EP2531521A4 | 2014-04-02 | JOLLY JAMES F; IDO HOROKI; MATSUBARA HIROTAKA; TAKAHASHI TETSUYA; NISHIO KYOICHI |
| 19 | WOUND DEBRIDEMENT COMPOSITIONS CONTAINING SEAPROSE AND METHODS OF WOUND TREATMENT USING SAME | EP12723779.0 | 2012-05-11 | EP2707019A1 | 2014-03-19 | SHI, Lei; JOVANOVIC, Aleksa; CARSON, Dennis |
| Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds. | ||||||
| 20 | グルテン不耐性に対するプロテアーゼの使用 | JP2016014685 | 2016-01-28 | JP2016112019A | 2016-06-23 | ジェームズ エフ.ジョリー; 井戸 宏樹; 松原 寛敬; 高橋 哲也; 西尾 享一 |
| 【課題】酵素組成物を提供する。 【解決手段】GDEP;GDEP−LGG;GDEP−M;GDEP−LNA;GDEP−2A;GDEP−AH;パパイン;アオルシン;アオルシンに対して少なくとも約80%相同であるアミノ酸配列を有する酸性セリンプロテアーゼポリペプチド、又はその断片;CPY;CPYに対して少なくとも約80%相同であるアミノ酸配列を有する酵素、又はその断片;セミアルカリプロテアーゼ;及びペニシリウム・シトリナムからの調製物、よりなる群から選択される組成物を含む、グルテンオリゴペプチドを開裂できる酵素カクテル。この酵素組成物はグルテン不耐性患者を治療するために使用でき、該不耐性は非セリアック性グルテン不耐性及び/又は非セリアック性グルテン感受性を含む。この酵素組成物はある種の個体(患者)のグルテン曝露の低減に利用できる。例えば予防としてグルテンオリゴペプチドへの曝露低減に使用できる。 【選択図】なし |
||||||
QQ群二维码
意见反馈
意见反馈